Updated Data Matrix Available

Market Value | Market Volume | Epidemiology | Clinical Trials | Patent Landscape | Regulatory Approvals

Bladder Cancer Biologics Pipeline Market Analysis by Drug Class – Angiogenesis Inhibitors, Cytotoxic T Lymphocyte Antigen 4 (CTLA4) Inhibitors, Programmed Cell Death 1 (PD1) Inhibitors, Programmed Cell Death Ligand 1 (PDL1) Inhibitors and Forecast 2024-2031


Report Specifications: Market Size, Market Share, Growth Trends, Forecast, Geography

Bladder cancer is one of the most common cancers in the U.S., affecting men more likely than women, with an estimated 77,000 new cases predicted to be diagnosed in 2016. Bladder cancers are clinically categorized as non-muscle invasive (NMIBC), muscle invasive (MIBC) or metastatic, and approximately 90% of cases of bladder cancer are urothelial (transitional cell) carcinomas. For NMIBC and MIBC, transurethral resection of bladder tumour (TURBT) is standard; adjuvant intravesical (local) chemotherapy or immunotherapy with bacillus Calmette–Guerin (BCG) may follow. For MIBC, cystectomy with or without (neo) adjuvant chemotherapy may be recommended. Chemotherapy, most commonly comprising platinum agents, has remained the mainstay of treatment for metastatic disease over the past decades. Immunotherapy has seen and continues to deliver promising results in the treatment of bladder cancer, there are numerous immune-based treatments for bladder cancer currently in development, with immunotherapy clinical trials for bladder cancer patients on the rise. The biological pipeline drugs considered in the study includes programmed cell death ligand 1 (PDL1) inhibitors as atezolizumab (Tecentriq), durvalumab and avelumab; programmed cell death 1 (PD1) inhibitors as pembrolizumab (Keytruda) and nivolumab (Opdivo); cytotoxic T lymphocyte antigen 4 (CTLA4) inhibitors as tremelimumab; and angiogenesis inhibitors as ramucirumab (Cyramza). Bladder cancer immunotherapy has significantly reduced the risk of recurrence for bladder cancer, while also increasing the percentage of patients with complete response post-surgery. New and developing bladder cancer immunotherapies have the potential to reduce recurrence rates and improve survival rates for patients with bladder cancer.

The global bladder cancer biologics pipeline market analysis segmentation is based on drug class – angiogenesis inhibitors, cytotoxic t lymphocyte antigen 4 (CTLA4) inhibitors, programmed cell death 1 (PD1) inhibitors, and programmed cell death ligand 1 (PDL1) inhibitors.

The global bladder cancer biologics pipeline market analysis research report provides market size ($Million 2021 to 2031), market share estimates, growth trends and forecast (CAGR%, 2021 to 2031), with target or mechanism of action, and development status (clinical phase). The global bladder cancer biologics pipeline market analysis research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. In addition, the global market report provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis, and market profitability analysis by key products and regions or countries.  The report also tracks the major competitors operating in the global market by company overview, financial snapshot, major products, technologies, services offered and recent developments.

Major players operating in the global bladder cancer biologics pipeline market analysis and profiled in this report include Acerta Pharma, AstraZenenca, Bristol-Myers Squibb, Chugai Pharmaceutical Company, Cold Genesys, Eli Lilly, Heat Biologics, Merck & Co., Mirati Therapeutics, OncoGenex, Pfizer, Roche Holding AG, Spectrum Pharmaceuticals, and Taiho Pharmaceutical.

DATA INCLUDED: Bladder Cancer Biologics Pipeline Market Size, Bladder Cancer Biologics Pipeline Market Share, Bladder Cancer Biologics Pipeline Market Growth Rates, Bladder Cancer Biologics Pipeline Market Trends, and Bladder Cancer Biologics Pipeline Market Forecast to 2031

Market Data:

  • Base year for estimation: 2023
  • Actual estimates/Historical data: 2021-2031
  • Forecast period: 2024-2031
  • Market representation: Revenue in $million and CAGR % from 2024 to 2031
  • Regional scope: North America, Europe, Asia Pacific, Latin America, Rest of the World (Middle East & Africa)
  • Country scope: U.S., Canada, U.K., Germany, France, Italy, Spain, Japan, China, India, South Korea, Brazil, Mexico, South Africa, South Korea, Saudi Arabia, UAE and others.
  • Report coverage: Revenue forecast, company share, competitive landscape, growth factors, and trends
  • 15% free customization scope: Any specific or custom requirements, which is not currently within the scope of the report, will be provided as a part of customization.

Qualitative Analysis:

  • Industry overview
  • Industry trends
  • Market drivers and restraints
  • Key market opportunities
  • Market size
  • Growth trends
  • Porter’s five forces analysis
  • Market attractiveness analysis
  • Competitive landscape
    • Company overview
    • Financial performance
    • Product portfolio
    • Strategic insights
    • Recent developments

Quantitative Analysis:

  • Market size estimates and forecast for all segments
  • Regional market size estimated and forecast for major countries
  • Company financial performance
  • Competitive landscape: Company market share analysis

Please contact us for offers on individual or multiple report purchases.

  1. Introduction
  2. Executive Summary
    • Market Size Estimation ($million, 2021-2031)
    • Forecast Estimation ($million and CAGR%, 2024-2031)
  3. Research Methodology
  4. Market Landscape
    • Market Dynamics
      • Drivers
      • Barriers
      • Opportunities
    • Market Share Analysis
      • Companies
      • Drugs
    • Market Trends Analysis
      • Key success factors
      • Market Growth Rate
    • Market Attractiveness Analysis
    • Market Profitability Analysis
      • Buyer power
      • Supplier power
      • Barriers to entry
      • Threat of substitute products
      • Rivalry among firms in the industry
    • Distribution Channels
  5. Market Segmentation [refer Market Segments and Companies Tab]
    • Drug Class or Drug (Brand) Type
    • Drug or Disorder Test
    • Indication Type
    • Drug Treatment
    • Mechanism of Action
    • Therapeutic Area or Nature of Application
    • End User Groups
  6. Geography (Region, Country)
    • North America (U.S., Canada)
    • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
    • Asia Pacific (Japan, China, India, Rest of APAC)
    • Latin America (Brazil, Mexico, Rest of LA)
    • Rest of the World (Middle East & Africa)
  7. Regulatory Overview 
    • IND, NDA filed, FDA, EMEA Approvals
  8. Pipeline Analysis(Phase 1, 2 and 3 Drugs)
    • Phase 3 Drugs Forecast Estimation (Approval to 2031)
    • Phase 1 and 2 Drugs – Qualitative Analysis
  9. Company Profiles [refer Market Segments and Companies Tab]
    • Company Overview
    • Financial Snapshot
    • Product Portfolio
    • Business Strategies
    • Recent Developments
  10. Recommendations
  11. References

Key Questions Answered:
1. What are the factors driving and limiting this market, key success factors and challenges?
2. Which are the leading competitors in the market, their market share, profitability and key trends by product, technology, services portfolio?
3. How do markets perform between countries and regions?
4. What market segments are contributing to maximum share and greatest growth?
5. What are the product or procedure volumes by country and regions?

Actionable Insights Included:
1. Product portfolio matrix (Share vs. Growth)
2. Market attractiveness (Region vs. Growth)
3. Spot matrix (Product vs. Region)
4. Geographic distribution matrix (Share vs. Growth)

Bladder Cancer Biologics Pipeline Market

1. Drug Class
1.1. Angiogenesis Inhibitors
1.2. Cytotoxic T Lymphocyte Antigen 4 (CTLA4) Inhibitors
1.3. Programmed Cell Death 1 (PD1) Inhibitors
1.4. Programmed Cell Death Ligand 1 (PDL1) Inhibitors

2. Geography
2.1. North America (U.S., Canada)
2.2. Latin America (Brazil, Mexico, Rest of LA)
2.3. Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
2.4. Asia Pacific (Japan, China, India, Rest of APAC
2.5. Rest of the World

3. Company Profiles
3.1. Acerta Pharma
3.2. AstraZenenca
3.3. Bristol-Myers Squibb
3.4. Chugai Pharmaceutical Company
3.5. Cold Genesys
3.6. Eli Lilly
3.7. Heat Biologics
3.8. Merck & Co.
3.9. Mirati Therapeutics
3.10. OncoGenex
3.11. Pfizer
3.12. Roche Holding AG
3.13. Spectrum Pharmaceuticals
3.14. Taiho Pharmaceutical

    Request ToC / Sample Report

    Full Name*

    Company Email*

    Phone Number* [Please add country code]



    Secure Online Payment

    iHealthcareAnalyst, Inc.

    Contact Address

    US Office: 2109, Mckelvey Hill Drive, Maryland Heights, MO 63043, United States
    Phone: +1 (314) 315-4764
    India Office: 5, Shilpa Chambers, Opp. J. M. Road, Shivajinager, Pune 411005, India
    Phone: +91 (20) 25898524
    Email: sales@ihealthcareanalyst.com